Want to see FR:GDS full AI Analyst Report?
Top Page
Ramsay Generale de Sante
(GDS)
Select Model
Select Model
Rating:49Neutral
Price Target:
€9.00
▼(-3.64% Downside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weakened financial performance: a sharp recent revenue decline, multiple years of net losses, and high leverage/negative ROE. Technicals provide some support (trading above key moving averages with neutral-to-positive momentum), but valuation remains unattractive/uncertain due to negative earnings and no dividend yield data.
Positive Factors
Strong Gross Margins
Stable gross margins indicate that the core hospital and healthcare services model retains substantial economic value after direct service costs. This provides a durable base for funding operations and future investment, even while operating expenses and below-the-line costs pressure net earnings.
Negative Factors
Sharp Revenue Contraction
A 32.8% revenue decline materially weakens the company’s growth profile and indicates that recent activity, pricing, or mix has not been sustained. If the contraction persists, lower revenue absorption could continue to pressure operating margins and reduce the cash available for investment and debt reduction.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Stable gross margins indicate that the core hospital and healthcare services model retains substantial economic value after direct service costs. This provides a durable base for funding operations and future investment, even while operating expenses and below-the-line costs pressure net earnings.
Read all positive factors
Ramsay Generale de Sante (GDS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€986.63M
Dividend Yield11.04%
Average Volume (3M)1.34K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth2.65%
EPS Growth10.71%
CountryFR
Employees40,388
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.53
Shares Outstanding110,389,690
10 Day Avg. Volume1,208
30 Day Avg. Volume1,341
Financial Highlights & Ratios
PEG Ratio5.92
Price to Book (P/B)1.05
Price to Sales (P/S)0.22
P/FCF Ratio3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ramsay Generale de Sante Business Overview & Revenue Model
Company Description
Ramsay Générale de Santé S.A., headquartered in Paris, France, manages a network of hospitals across the nation. These facilities provide a wide spectrum of healthcare services, including specialized care in anesthesia, oncology, cardiology, derma...
How the Company Makes Money
GDS generated revenue primarily by operating private hospitals and clinics and billing for healthcare services delivered to patients. Key revenue streams typically included (i) reimbursement and payments for inpatient hospitalizations and day-case...
Ramsay Generale de Sante Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
35
Negative
Cash Flow
58
Neutral
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.38B | 5.24B | 5.01B | 4.70B | 4.30B |
| Gross Profit | 4.23B | 4.08B | 3.94B | 3.72B | 3.41B |
| EBITDA | 628.20M | 599.70M | 584.90M | 647.30M | 677.10M |
| Net Income | -48.30M | -54.10M | -53.90M | 49.40M | 118.40M |
Balance Sheet | |||||
| Total Assets | 6.68B | 6.84B | 6.90B | 6.96B | 6.79B |
| Cash, Cash Equivalents and Short-Term Investments | 311.10M | 384.00M | 381.30M | 362.90M | 143.50M |
| Total Debt | 4.05B | 4.08B | 4.06B | 4.15B | 3.97B |
| Total Liabilities | 5.53B | 5.66B | 5.67B | 5.68B | 5.55B |
| Stockholders Equity | 1.12B | 1.15B | 1.19B | 1.25B | 1.21B |
Cash Flow | |||||
| Free Cash Flow | 380.80M | 550.90M | 418.30M | 426.70M | 68.90M |
| Operating Cash Flow | 524.70M | 693.70M | 586.80M | 598.90M | 262.50M |
| Investing Cash Flow | -132.90M | -138.40M | -180.50M | -175.40M | -471.10M |
| Financing Cash Flow | -454.00M | -550.20M | -401.50M | -197.10M | -264.20M |
Ramsay Generale de Sante Technical Analysis
Negative
9.34
Price Trends
10.18
Negative
10.59
Negative
10.55
Negative
Market Momentum
-0.32
Positive
27.50
Positive
5.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Negative. The current price of 9.34 is below the 20-day moving average (MA) of 9.57, below the 50-day MA of 10.18, and below the 200-day MA of 10.55, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 27.50 is Positive, neither overbought nor oversold. The STOCH value of 5.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:GDS.
Ramsay Generale de Sante Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €469.03M | 7.12 | 7.82% | 2.16% | -0.44% | 5958.14% | |
61 Neutral | €249.04M | 9.68 | 7.63% | 7.95% | 10.06% | 21.64% | |
60 Neutral | €134.54M | -9.17 | -5.44% | 2.17% | -0.98% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €133.97M | 2.32 | 49.70% | 0.58% | -1.79% | 10979.07% | |
51 Neutral | €1.63B | -6.15 | -15.35% | 0.84% | 3.92% | 31.20% | |
49 Neutral | €986.63M | -16.18 | -4.25% | 11.04% | 2.65% | 10.71% |
* General Sector Average
FR:GDS
Ramsay Generale de Sante
8.94
0.02
0.22%
FR:BLC
Bastide le Confort Medical
18.32
-6.48
-26.13%
FR:ALCGM
Cegedim
9.81
-1.89
-16.15%
FR:ELIOR
Elior Group SA
1.85
-0.91
-33.07%
FR:LNA
LNA Sante SA
23.90
1.11
4.87%
FR:EMEIS
Orpea SA
10.08
-5.63
-35.84%
Ramsay Generale de Sante Corporate Events
Ramsay Santé Overhauls Governance as Parent Plans Stake Distribution
Oct 19, 2026
Ramsay Santé has announced a significant governance reshuffle tied to the planned in‑specie distribution of Ramsay Health Care Limited’s 52.79% stake in the company to RHC’s own shareholders. Several RHC‑nominated dire...
Ramsay Santé lifts revenue and unveils 2030 strategy as refinancing boosts flexibility
Oct 6, 2026
Ramsay Santé reported annual revenue of €5.38 billion to June 2026, up 3.3% (2.3% like-for-like), with EBITDA rising 2.6% to €638 million and margins holding at 11.9% amid disciplined cost control and ongoing public funding pressu...
Ramsay Santé launches “Connecting Care 2030” and reshapes shareholder base
Sep 17, 2026
Ramsay Santé has launched its new strategic roadmap, “Connecting Care 2030”, building on the success of the “Yes We Care 2025” plan that transformed the group into one of Europe’s largest integrated healthcare pl...
Ramsay Santé lifts revenue, steadies leverage as it readies 2030 strategy and ownership shift
Aug 26, 2026
Ramsay Santé reported provisional annual revenue of €5.38 billion for the year to June 2026, up 3.3% year on year, with like-for-like growth of 2.3% driven by day hospitalisation in France and strong Nordic performance including the new...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.